Griffin Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$19.7M Sell
78,095
-630
-0.8% -$136K 2.07% 8
2026
Q1
$17.1M Sell
78,725
-2,204
-3% -$489K 1.93% 11
2025
Q4
$18.5M Buy
80,929
+734
+0.9% +$167K 2% 10
2025
Q3
$18.6M Buy
80,195
+60
+0.1% +$12.2K 2.09% 7
2025
Q2
$14.9M Sell
80,135
-1,411
-2% -$262K 1.76% 11
2025
Q1
$17.1M Sell
81,546
-110
-0.1% -$21.4K 2.09% 6
2024
Q4
$14.5M Buy
81,656
+1,074
+1% +$197K 1.71% 12
2024
Q3
$15.9M Sell
80,582
-2,946
-4% -$550K 1.78% 6
2024
Q2
$14.3M Buy
83,528
+74
+0.1% +$12.3K 1.66% 9
2024
Q1
$15.2M Sell
83,454
-5,896
-7% -$1.02M 1.81% 7
2023
Q4
$13.8M Sell
89,350
-193
-0.2% -$28.1K 1.76% 7
2023
Q3
$13.3M Buy
89,543
+20
+0% +$2.94K 1.9% 5
2023
Q2
$12.1M Buy
89,523
+1,526
+2% +$224K 1.63% 8
2023
Q1
$14M Sell
87,997
-823
-0.9% -$126K 1.96% 4
2022
Q4
$14.4M Buy
88,820
+2,551
+3% +$391K 2.16% 4
2022
Q3
$11.6M Sell
86,269
-431
-0.5% -$61.8K 1.92% 5
2022
Q2
$13.3M Sell
86,700
-7,643
-8% -$1.17M 2.12% 6
2022
Q1
$15.3M Sell
94,343
-14,063
-13% -$2.04M 1.98% 5
2021
Q4
$14.7M Buy
108,406
+4,965
+5% +$586K 1.82% 7
2021
Q3
$11.2M Sell
103,441
-4,600
-4% -$526K 1.43% 14
2021
Q2
$12.2M Buy
108,041
+202
+0.2% +$22.8K 1.47% 9
2021
Q1
$11.7M Buy
107,839
+2,063
+2% +$221K 1.49% 8
2020
Q4
$11.3M Buy
105,776
+4,946
+5% +$475K 1.5% 8
2020
Q3
$8.83M Sell
100,830
-20,803
-17% -$1.96M 1.36% 12
2020
Q2
$11.9M Buy
121,633
+4,775
+4% +$420K 1.91% 6
2020
Q1
$8.9M Buy
116,858
+40
+0% +$3.41K 1.69% 9
2019
Q4
$10.3M Buy
116,818
+659
+0.6% +$54.7K 1.45% 8
2019
Q3
$8.8M Buy
116,159
+649
+0.6% +$44.5K 1.37% 11
2019
Q2
$8.4M Buy
115,510
+1,976
+2% +$155K 1.07% 18
2019
Q1
$9.15M Sell
113,534
-16,189
-12% -$1.32M 1.29% 14
2018
Q4
$12M Buy
129,723
+5,816
+5% +$511K 2.02% 6
2018
Q3
$11.7M Buy
123,907
+1,143
+0.9% +$108K 1.72% 10
2018
Q2
$11.4M Sell
122,764
-2,030
-2% -$198K 2.06% 8
2018
Q1
$11.8M Sell
124,794
-3,824
-3% -$420K 2.15% 7
2017
Q4
$12.4M Sell
128,618
-20,289
-14% -$1.91M 2.21% 6
2017
Q3
$13.2M Buy
148,907
+23,128
+18% +$1.76M 2.39% 4
2017
Q2
$9.12M Buy
+125,779
New +$8.46M 2.44% 6
2015
Q4
$7.49M Sell
126,364
-4,330
-3% -$249K 3.15% 5
2015
Q3
$7.11M Sell
130,694
-1,517
-1% -$98.7K 2.96% 5
2015
Q2
$8.88M Sell
132,211
-4,422
-3% -$289K 3.41% 4
2015
Q1
$8M Buy
136,633
+7,297
+6% +$441K 2.32% 9
2014
Q4
$8.46M Sell
129,336
-4,016
-3% -$253K 2.25% 11
2014
Q3
$7.7M Sell
133,352
-9,329
-7% -$518K 2.3% 10
2014
Q2
$8.05M Buy
142,681
+7,517
+6% +$394K 2.52% 7
2014
Q1
$6.95M Buy
135,164
+1,128
+0.8% +$57K 2.25% 14
2013
Q4
$7.08M Buy
134,036
+10,007
+8% +$492K 2.29% 13
2013
Q3
$5.55M Buy
124,029
+1,022
+0.8% +$45.3K 1.81% 18
2013
Q2
$5.08M Buy
+123,007
New +$5.38M 1.84% 19

Other funds holding ABBV

Griffin Asset Management's ABBV Position: Q2 2026 in Review

Griffin Asset Management reduced its AbbVie (ABBV) stake by 0.8% in Q2 2026, selling an estimated $136K and leaving 78,095 shares worth $19.7M. The position accounts for 2.07% of the portfolio, ranked #8.

Griffin Asset Management first reported a position in ABBV in Q2 2013 and has held it in 48 quarters since. 4,189 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Griffin Asset Management held 78,095 shares of AbbVie worth $19.7M as of Q2 2026.
  • Griffin Asset Management sold 630 AbbVie shares in Q2 2026, an estimated $136K.
  • AbbVie made up 2.07% of Griffin Asset Management's portfolio in Q2 2026, its #8 holding.
  • Griffin Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 48 quarters since.
  • 4,189 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Griffin Asset Management's 13F filing for Q2 2026, filed 23 Jul 2026.